ADVANCEMENTS IN CANCER PHARMACOTHERAPY: TARGETED THERAPIES AND IMMUNOTHERAPY STRATEGIES, A REVIEW

H MAQBOOL; U YASIN; L SHAWAL; F ZULFIQAR; N FATIMA; W HASAN; H NASIM; M ISMAIL; MA RAFIQ

doi:10.54112/bcsrj.v2024i1.1025

Authors

H MAQBOOL Department Chemistry, University of Agriculture Faisalabad, Punjab Pakistan
U YASIN Faculty of Veterinary Sciences (FVS), University of Veterinary and Animal Sciences, Lahore, Punjab, Pakistan
L SHAWAL Centre of Biotechnology and Microbiology, University of Peshawar, Pakistan
F ZULFIQAR Department of Pharmacy, The University of Faisalabad, Punjab, Pakistan
N FATIMA Department of Pharmaceutics, The Islamia University Bahawalpur, Punjab Pakistan
W HASAN Assistant Pharmacist, Chemico-bacteriological laboratory, Government of Sindh Karachi, Pakistan
H NASIM Departmen of Biosciences, COMSATS University Islamabad, Pakistan
M ISMAIL Department of Physics, NED University of Engineering and Technology Karachi Sindh, Pakistan
MA RAFIQ Department of Pharmaceutical Science, Government College University Faisalabad, Punjab Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1025

Keywords:

Immunotherapy, Targeted Therapies, Pharmacotherapy, Cart T-Cell, Checkpoint Inhibitors

Abstract

The development of immunotherapy and targeted medicines has fundamentally changed and revolutionized the field of cancer treatment. These cutting-edge methods, which include cancer vaccines, CAR-T cell therapy, checkpoint inhibitors, monoclonal antibodies, and small molecule inhibitors, are not only therapeutic interventions but also revolutionary instruments. They are carefully crafted to interfere with particular molecular pathways that propel tumors' growth and spread and use patients' immune systems to fight cancerous cells. This research aims to thoroughly investigate the mechanisms, clinical uses, efficacy, obstacles, current developments, and prospects of these noteworthy achievements in cancer pharmacotherapy. The paradigm changes in cancer, combining immunotherapy and targeted medicines, provide individualized treatment plans that consider each patient's particular needs, offering a sense of reassurance and confidence in the treatment process.

Downloads

Download data is not yet available.

References

Al-Lazikani, B., Banerji, U., & Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 30(7), 679-692.

Arora, A., & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. Journal of Pharmacology and Experimental Therapeutics, 315(3), 971-979.

Barot, S., Patel, H., Yadav, A., & Ban, I. (2023). Recent advancement in targeted therapy and the role of emerging technologies to treat cancer. Medical Oncology, 40(11), 324.

Baselga, J., Cortés, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., ... & Swain, S. M. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine, 366(2), 109-119.

Bellmunt Molins, J., Powles, T., & Vogelzang, N. J. (2017). A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treatment Reviews. 2017 Mar; 54: 58-67.

Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., ... & Bhat, A. A. (2023). Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Journal of translational medicine, 21(1), 449.

D'Aniello, A., Del Bene, A., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., ... & Messere, A. (2024). The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines. Journal of Peptide Science, e3596.

Davis, S. J., Smith, R. H., & Wong, C. K. (2023). Bispecific Antibodies in Cancer Therapy: Recent Advances and Clinical Applications. Clinical Cancer Research, 29(1), 12-23.

Drenth‐van Maanen, A. C., Wilting, I., & Jansen, P. A. (2020). Prescribing medicines to older people—How to consider the impact of aging on human organs and body functions. British journal of clinical pharmacology, 86(10), 1921-1930.

Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., ... & Sawyers, C. L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031-1037.

Faazal, B., Qasim, M., Mumtaz, S., Iftikhar, M., Khalid, I., Muzaffar, M. J., Nisar, H., & Adrees, M. (2023). Important air pollutants influence crop quality and quantity in Pakistan. In Advances in Botanical Research (Vol. 108, pp. 109–144). Elsevier.

Fatima, R., Basharat, U., Safdar, A., Haidri, I., Fatima, A., Mahmood, A., Ullah, Q., Ummer, K., & Qasim, M. (2024). AVAILABILITY OF PHOSPHOROUS TO THE SOIL, THEIR SIGNIFICANCE FOR ROOTS OF PLANTS AND ENVIRONMENT. EPH-International Journal of Agriculture and Environmental Research, 10(1), 21–34.

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., ... & Cheng, A. L. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine, 382(20), 1894-1905.

Gabizon, A., Barenholz, Y., & Shapiro, H. (2022). Liposomal Doxorubicin: Mechanisms of Action and Strategies for Improved Delivery. Cancer Research, 82(4), 567-577.

Gide TN, Quek C, Menzies AM, et al. (2019). Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell. 35(2), 238–55. e236.

Haidri, I., Fatima, N., Abdullah, M., Ilyas, A., Parveen, A., Afzal, R., Shahbaz, M., Batool, M., & Qasim, M. (2024). SYNTHESIS CHARACTERIZATION AND APPLICATIONS OF NANOPARTICLES IN ENVIRONMENTAL DETOXIFICATION. EPH-International Journal of Agriculture and Environmental Research, 10(1), 43–57.

Haidri, I., Ishfaq, A., Shahid, M., Shahzad, T., Hussain, S., & Mahmood, F. (2024). Green Nanoparticles for Textile Wastewater Treatment: The Current Insights. Microbes Based Approaches for the Management of Hazardous Contaminants, 277–292.

Haidri, I., Qasim, M., Shahid, M., Farooq, M. M., Abbas, M. Q., Fatima, R., Shoukat, W., & Ullah, Q. (2024). Enhancing the Antioxidant Enzyme Activities and Soil Microbial Biomass of tomato plants against the stress of Sodium Dodecyl Sulfate by the application of bamboo biochar. Remittances Review, 9(2), 1609–1633.

Haidri, I., Shahid, M., Hussain, S., Shahzad, T., Mahmood, F., Hassan, M. U., Al-Khayri, J. M., Aldaej, M. I., Sattar, M. N., & Rezk, A. A.-S. (2023). Efficacy of Biogenic Zinc Oxide Nanoparticles in Treating Wastewater for Sustainable Wheat Cultivation. Plants, 12(17), 3058.

Halli-Tierney AD, Scarbrough C, Carroll D. (2019). Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 100, 32–38.

Hammerstrom, A. E., Cauley, D. H., Atkinson, B. J., & Sharma, P. (2011). Cancer immunotherapy: sipuleucel‐T and beyond. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 31(8), 813-828.

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018). Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. International immunopharmacology, 62, 29-39.

Hegde, P. S., Chen, D. S., & Mellman, I. (2020). Tumor microenvironment: moving target for cancer therapy. Nature Reviews Drug Discovery, 19(3), 173-186.

Hodi, F. S., O'Day, S. J., McDermott, D. F., et al. (2023). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 368(14), 1271-1280.

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 13(10), 714-726.

Hu, Z., Ott, P. A., & Wu, C. J. (2018). Towards personalized, tumor-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 18(3), 168-182.

Hussain, S. R., Rashid, M. Z., Haidri, I., Shafqat, U., & Mahmood, F. (2024). Assessing global good agricultural practices standard adoption: insights from fruit and vegetable farmers in Pakistan. Italian Journal of Food Safety.

Janjigian, Y. Y., Goyal, L., & Du, J. (2023). Overcoming Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer: Current Strategies and Future Directions. Journal of Clinical Oncology, 41(5), 951-964.

Janku, F., Huang, H. J., & Angelo, L. S. (2018). Targeted therapies: focusing on the cellular targets in cancer therapy. The Lancet Oncology, 19(10), e563-e573.

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., ... & Schellhammer, P. F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363(5), 411-422.

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., ... & Reardon, D. A. (2019). Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 565(7738), 234-239.

Kumar, S., Patel, P., & Kumar, R. (2023). Targeted Therapies in Cancer Treatment: A Review of the Latest Developments and Mechanisms of Action. Oncology Reports, 40(3), 1675-1687.

Kumar, V., Rajput, S., & Patel, M. (2023). Personalized Chemotherapy: The Role of Genetic Profiling in Optimizing Treatment. Oncology Reviews, 17(1), 15-25.

Lee S, Margolin K. (2011). Cytokines in cancer immunotherapy. Cancers (Basel). 3(4), 3856–93.

Llombart Cussac, A., de la Haba Rodriguez, J., Ruiz Simon, A., Álvarez López, I., & Cortés Castán, J. (2013). SEOM clinical guidelines for the management of metastatic breast cancer 2013. Clinical and Translational Oncology, 15, 1004-1010.

Lufti, F., Patel, A., Mehta, J., Goyal, A., & Dahiya, S. (2023). Second-line treatment with CAR T-cell therapy for large B-cell lymphoma. Clinical Advances in Hematology & Oncology, 21(4), 170-8.

Maleki Vareki S, Garrigos C, Duran I. (2017). Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 116, 116–24.

Maude, S. L., Laetsch, T. W., Buechner, J., et al. (2023). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 378(5), 439-448.

Mendelsohn, J., & Baselga, J. (2006, August). Epidermal growth factor receptor targeting in cancer. In Seminars in oncology (Vol. 33, No. 4, pp. 369-385). WB Saunders.

Menon S, Shin S, Dy G. (2016). Advances in cancer immunotherapy in solid tumors. Cancers (Basel). 8(12), E106.

Millimouno, F. M., Dong, J., Yang, L., Li, J., & Li, X. (2014). Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer prevention research, 7(11), 1081-1107.

Milling L, Zhang Y, Irvine DJ. (2017). Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 114, 79–101.

Mok, T. S., Wu, Y. L., & Ahn, M. J. (2023). Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Review of Clinical Outcomes and Strategies. The Lancet Oncology, 24(4), 453-464.

Müller, V., Alix-Panabières, C., & Pantel, K. (2010). Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. European Journal of Cancer, 46(7), 1189-1197.

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., ... & Wu, C. J. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547(7662), 217-221.

Penson, R. T., Valencia, R. V., & Mirza, M. R. (2021). Niraparib in BRCA-Mutated Ovarian Cancer: Clinical Outcomes and Management Strategies. Gynecologic Oncology, 161(2), 284-292.

Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355.

Ribas, A., Wolchok, J. D., & Hodi, F. S. (2019). Combined blockade of PD-1 and CTLA-4 in melanoma. New England Journal of Medicine, 380(14), 1348-1360.

Sahin, U., et al. (2018). "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer." Nature, 547(7662), 222-226.

Sajid, S. A., Tehseen, P., Mahmood, U., Ghaffar, A., Qasim, M., Arooj, R., Tahir, T., & Rafique, Z. (2024). Role of Sustainable Alternatives to Petrochemical Based Plastics in Achieving the SDGS. Indonesian Journal of Agriculture and Environmental Analytics, 3(1), 35–52.

Sanmamed, M. F., & Chen, L. (2018). A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell, 175(2), 313-326.

Sawyers, C. (2004). Targeted cancer therapy. Nature, 432(7015), 294-297.

Schiller, J., Lowy, D., & Markowithz, L. (2012). Human papillomavirus vaccines. Vaccines. 6th ed. Philadelphia, PA: Saunders, 235-256.

Sharma, P., & Allison, J. P. (2020). The future of immune checkpoint therapy. Science, 348(6230), 56-61.

Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: a cancer journal for clinicians, 64(1).

Skolnik, J., Reardon, D., Brem, S., Desai, A., Bagley, S., Kurz, S., ... & Boyer, J. (2020). P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM).

Sledge, G. W., Pfister, D., & Barlow, W. E. (2022). The Evolution of Chemotherapy: From Cytotoxic Agents to Targeted Therapies. Journal of Clinical Oncology, 40(8), 1105-1112.

Stevens, K. R., Masters, K. S., Imoukhuede, P. I., Haynes, K. A., Setton, L. A., Cosgriff-Hernandez, E., ... & Eniola-Adefeso, O. (2021). Fund black scientists. Cell, 184(3), 561-565.

Sutherland, S. I., Ju, X., Horvath, L. G., & Clark, G. J. (2021). Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer. Frontiers in immunology, 12, 641307.

Toh JJ, Zhang H, Soh YY, et al. (2023). Prevalence and health outcomes of polypharmacy and hyper polypharmacy in older adults with frailty: A systematic review and meta-analysis. Ageing Res Rev. 83, 101811.

Topalian, S. L., Hodi, F. S., & Brahmer, J. R. (2023). Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine, 368(26), 2541-2552.

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., ... & Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD–1 antibody in cancer. New England Journal of Medicine, 366(26), 2443-2454.

Ullah, Q., Qasim, M., Abaidullah, A., Afzal, R., Mahmood, A., Fatima, A., & Haidri, I. (2024). EXPLORING THE INFLUENCE OF NANOPARTICLES AND PGPRS ON THE PHYSICO-CHEMICAL CHARACTERISTICS OF WHEAT PLANTS: A REVIEW. EPH-International Journal of Agriculture and Environmental Research, 10(1), 1–9.

Ummer, K., Khan, W., Iqbal, M. A., Abbas, M. Q., Batool, R., Afzal, R., Ullah, Q., Qasim, M., & Haidri, I. (2023). THE INTRICACIES OF PHOTOCHEMICAL SMOG: FROM MOLECULAR INTERACTIONS TO ENVIRONMENTAL IMPACT. EPH-International Journal of Applied Science, 9(2), 23–33.

US Food and Drug Administration. (2016). Pembrolizumab (KEYTRUDA) checkpoint inhibitor. Available at: https://www. fda. gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-checkpoint-inhibitor (Accessed June 26, 2021).